» Articles » PMID: 38680606

All-cause and Infection-attributable Mortality Amongst Adults With Bloodstream Infection-a Population-based Study

Overview
Date 2024 Apr 29
PMID 38680606
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Bloodstream infections (BSIs) are common, life-threatening infections. However, it remains unclear whether deaths following BSIs are primarily from uncontrolled infection or underlying comorbidities. We aimed to determine the overall mortality, infection-attributable mortality, and causes of death for four leading BSI pathogens.

Methods: This retrospective cohort study was conducted within the Secure Anonymized Information Linkage Databank, containing anonymized population-scale electronic health record data for Wales, UK. We included adults with , spp, , and BSI between 2010 and 2022 using linked data from Public Health Wales and the Office for National Statistics. Thirty-day all-cause and sepsis-specific mortality, as a proxy for infection-attributable mortality, were compared using Cox proportional hazards and competing risk regression, respectively.

Results: We identified 35 691 adults with BSI (59.6% ). Adjusted analyses revealed that all organisms had a higher 30-day mortality versus with the highest (hazard ratio, 1.96 [1.76-2.17], < .001). Cancer was the leading cause of death following BSIs for all organisms, particularly deaths occurring between 30 and 90 days (35.9%). A total of 25.5% of deaths within 30 days involved sepsis. Methicillin-resistant was associated with the highest sepsis mortality versus (hazard ratio, 2.56 [2.10-3.12], < .001). Peak C-reactive protein was positively associated with increased sepsis mortality ( < .001).

Conclusions: This population-level study challenges the assumption that most deaths following BSIs are directly attributable to uncontrolled infection, particularly subacutely more than 30 days from BSI. Our findings underscore the need for reevaluating clinical trial design and developing better preventive strategies for BSIs.

Citing Articles

Demographics, epidemiology, mortality and difficult-to-treat resistance patterns of bacterial bloodstream infections in the global US Military Health System from 2010 to 2019: a retrospective cohort study.

Vostal A, Grance M, Powers 3rd J, Kadri S, Warner S, Chukwuma U BMJ Open. 2025; 15(3):e094861.

PMID: 40032367 PMC: 11877242. DOI: 10.1136/bmjopen-2024-094861.


Demographics, Epidemiology, Mortality, and Difficult-To-Treat Resistance Patterns of Bacterial Bloodstream Infections in the Global United States Military Health System from 2010-2019: A Retrospective Cohort Study.

Vostal A, Grance M, Powers 3rd J, Powers J, Kadri S, Warner S medRxiv. 2025; .

PMID: 39802776 PMC: 11722484. DOI: 10.1101/2024.10.02.24314780.


Iliopsoas Abscess Related to Pseudomonas aeruginosa: A Case Report.

Ueda K, Hayashi K, Azuma S, Hayashi M Cureus. 2024; 16(10):e72463.

PMID: 39600748 PMC: 11589657. DOI: 10.7759/cureus.72463.


Sex Disparities in Staphylococcus aureus Bacteremia Mortality.

Carter B, Underwood J JAMA Netw Open. 2024; 7(10):e2441502.

PMID: 39476238 PMC: 11525600. DOI: 10.1001/jamanetworkopen.2024.41502.


Beyond Human Babesiosis: Prevalence and Association of Coinfection with Mortality in the United States, 2015-2022: A Retrospective Cohort Study.

Ssentongo P, Venugopal N, Zhang Y, Chinchilli V, Ba D Open Forum Infect Dis. 2024; 11(10):ofae504.

PMID: 39381028 PMC: 11460071. DOI: 10.1093/ofid/ofae504.

References
1.
Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

2.
Gotland N, Uhre M, Mejer N, Skov R, Petersen A, Larsen A . Long-term mortality and causes of death associated with Staphylococcus aureus bacteremia. A matched cohort study. J Infect. 2016; 73(4):346-57. DOI: 10.1016/j.jinf.2016.07.005. View

3.
Paulsen J, Mehl A, Askim A, Solligard E, Asvold B, Damas J . Epidemiology and outcome of Staphylococcus aureus bloodstream infection and sepsis in a Norwegian county 1996-2011: an observational study. BMC Infect Dis. 2015; 15:116. PMC: 4351681. DOI: 10.1186/s12879-015-0849-4. View

4.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R . Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3.... Lancet Infect Dis. 2020; 21(2):226-240. DOI: 10.1016/S1473-3099(20)30796-9. View

5.
Buchman T, Simpson S, Sciarretta K, Finne K, Sowers N, Collier M . Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012-2018. Crit Care Med. 2020; 48(3):276-288. PMC: 7017943. DOI: 10.1097/CCM.0000000000004224. View